PANGEA-HIV: phylogenetics for generalised epidemics in Africa

More HIV-infected individuals are receiving treatment, and life-expectancy of infected individuals has increased.1 However, the HIV epidemic continues and overall prevalence of HIV will increase.2 The burden of HIV remains highest in sub-Saharan Africa, with 75% of all HIV infections and adult prevalence at 5%.3 The use of ART to reduce individual viral loads and viral transmission rates has emerged as a promising approach to further slow the epidemic.4 Yet, how to implement treatment as prevention (in combination with pre-exposure prophylaxis or behavioural change interventions) in the most effective and efficient ways is unclear. PANGEA-HIV is funded primarily by the Bill & Melinda Gates Foundation, but builds on existing infrastructure, cohorts, and clinical trials that are funded independently by the the Bill & Melinda Gates Foundation, the US Centers for Disease Control and Prevention, the French Agence National de Recherches sur le Sida et les Hépatites Viral, the Medical Research Council (UK), the US National Institutes of Health, Wellcome Trust, World Bank STI Project, Henry M Jackson Foundation, and Fogarty Foundation.